CT-2584 is an angiogenesis inhibitor and lysophosphatidic acid acyltransferase inhibitor potentially for the treatment of cancer. CT-2584 inhibits phospholipid signaling. By choline-phosphate cytidylyltransferase (CT), CT-2584 caused de novo phospholipid biosynthesis via PA to be shunted away from phosphatidylcholine (PC) and into phosphatidylinositol (PI), the latter of which was doubled in a variety of CT-2584-treated tumor cell lines. CT-2584 effects a novel mechanism of cytotoxicity to cancer cells, involving a specific modulation of phospholipid metabolism. References: Bonfil RD. CT-2584 (Cell Therapeutics). Curr Opin Investig Drugs. 2001 Mar;2(3):424-7. PubMed PMID: 11575717.

纯度：≥98%

CAS：166981-13-1